Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway

Molecular Medicine Reports

Volumn 12, Issue 3, 2015, Pages 4530-4537

  Xia, Yang ^a   He, Zhicheng ^a   Liu, Bin ^a   Wang, Pengli ^a   Chen, Yijiang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

A549 DDP; Apoptosis; Cell cycle; Cisplatin; Lung cancer; Maternally expressed gene 3

Indexed keywords

BETA CATENIN; CISPLATIN; MEG3 PROTEIN; PROTEIN; PROTEIN P53; SURVIVIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; LONG UNTRANSLATED RNA; MEG3 NON-CODING RNA, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL CYCLE ARREST; CELL DENSITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LUNG CANCER; MALE; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY MECHANISM; RNA INTERFERENCE; UPREGULATION; WNT SIGNALING PATHWAY; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; LUNG; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; RNA, LONG NONCODING; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; WNT SIGNALING PATHWAY;

EID: 84935458872     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3897     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010.
2. Sánchez De Cos J, Sojo González MA, Montero M V, et al: Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer 63:140-145, 2009.
3. Chen CL, Ip SM, Cheng D, Wong LC and Ngan HY: Loss of imprinting of the IGF-II and H19 genes in epithelial ovarian cancer. Clin Cancer Res 6:474-479, 2000.
4. Yang F, Zhang L, Huo XS, et al: Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 54:1679-16 89, 2011.
5. Lai MC, Yang Z, Zhou L, et al: Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol 29:1810-1816, 2012.
6. Tsang WP and Kwok TT: Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene 26:4877-4881, 2007.
7. Fan Y, Shen B, Tan M, et al: Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J 281:1750-1758, 2014.
8. Jiang M, Huang O, Xie Z, et al: A novel long non-coding RNA-ARA: Adriamycin resistance-associated. Biochem Pharmacol 87:254-283, 2014.
9. Gejman R, Batista DL, Zhong Y, et al: Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 93:4119-4125, 2008.
10. Sun M, Xia R, Jin F, et al: Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol 35:1065-1073, 2014
11. Ying L, Huang Y, Chen H, et al: Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. Mol Biosyst 9:407-411, 2013.
12. Wang P, Ren Z and Sun P: Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. J Cell Biochem 113:1868-1874, 2012.
13. Qin R, Chen Z, Ding Y, Hao J, Hu J and Guo F: Long non-coding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis. Neoplasma 60:486-492, 2013.
14. Zhao X, Xu Z, Wang Z, et al.: RNA silencing of integrin-linked kinase increases the sensitivity of the A549 lung cancer cell line to cisplatin and promotes its apoptosis. Mol Med Rep 12:960-966, 2015
15. Stewart DJ: Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 106:djt356, 2014
16. Ward JH: NCCN Guidelines and the International Community. J Natl Compr Canc Netw 9:133-134, 2011.
17. Zhou Y, Zhong Y, Wang Y, et al: Activation of p53 by MEG3 non-coding RNA. J Biol Chem 282:24731-24742, 2007
18. Miao W, Liu X, Wang H, et al: p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. Mol Med Rep 11:4165-4173, 2015
19. Sadot E, Geiger B, Oren M and Ben-Ze'ev A: Down-regulation of beta-catenin by activated p53. Mol Cell Biol 21:6768-6781, 2001.
20. Wu MY, Xie X, Xu ZK, et al: PP2A inhibitors suppress migration and growth of PANC-1 pancreatic cancer cells through inhibition on the Wnt/beta-catenin pathway by phosphorylation and degradation of β-catenin. Oncol Rep 32:513-522, 2014
21. Gao Y, Liu Z, Zhang X, et al: Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells. Cancer Lett 336:231-239, 2013.
22. Ren S, Liu Y, Xu W, et al: Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol 190:2278-2287, 2013.
23. Schmidt LH, Spieker T, Koschmieder S, et al: The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol 6:1984-1992, 2011.
24. Xi YN, Xin XY and Ye HM: Effects of HMGA2 on malignant degree, invasion, metastasis, proliferation and cellular morphology of ovarian cancer cells. Asian Pac J Trop Med 7 289-292, 2014
25. Prensner JR, Iyer MK, Sahu A, et al: The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 45:1392-1398, 2013.
26. Yang F, Huo XS, Yuan SX, et al: Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell 49:1083-1096, 2013.
27. Chang A: Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71:3-10, 2011.
28. Strathdee G: Epigenetic markers and response to chemotherapy in cancer. Dis Markers 23:43-49, 2007
29. Liu Z, Sun M, Lu K, et al: The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21 (WAF1/CIP1) expression. PloS One 8:e77293, 2013.
30. Braconi C, Kogure T, Valeri N, et al: microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 30:4750-4756, 2011.
31. Butz H and Patocs A: Pituitary tumorigenesis: role of regulation of Wee1 kinase by microRNAs. In: Tumors of the Central Nervous System. Hayat M (ed). Vol 10. Springer, Dordrecht, pp141-150, 2013.
32. McCubrey JA, Steelman LS, Abrams SL, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249-279, 2006.
33. Bouwman P and Jonkers J: The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 12:587-598, 2012.
34. Cui J, Jiang W, Wang S, Wang L and Xie K: Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des 18:2464-2471, 2012.
35. Yang D, Welm A and Bishop JM: Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA 101:15100-15105, 2004